Expectations about treatment of idiopathic pulmonary fibrosis: Comparative survey of patients, carers and physicians (the RESPIR French survey).


Journal

Respiratory medicine and research
ISSN: 2590-0412
Titre abrégé: Respir Med Res
Pays: France
ID NLM: 101746324

Informations de publication

Date de publication:
May 2021
Historique:
received: 07 08 2020
revised: 22 12 2020
accepted: 27 12 2020
pubmed: 23 2 2021
medline: 29 10 2021
entrez: 22 2 2021
Statut: ppublish

Résumé

Idiopathic pulmonary fibrosis (IPF) is a severe chronic disease during which anxiety and depression are frequent comorbidities. Better knowledge of patients' expectations is needed to inform an action plan to improve medical care. To describe feelings and expectations of patients suffering from IPF and of their carers about antifibrotic therapy and compare them to what is perceived by their pulmonologist. National prospective study on practices and perceptions. Specific questionnaires were e-mailed to all 3276 pulmonologists in France who, in turn, invited patients and carers to participate in a survey. 147 pulmonologists, 161 patients and 144 carers participated in the survey. The role of the carer was evaluated as "important" or "very important" by more than 90% of participants, i.e. pulmonologists, patients or carers. Inconsistencies between how patients felt and how pulmonologists perceived them were identified: 88% of patients responded that they understood quite well what IPF is (vs. 75% of patients according to pulmonologists); 85.5% of patients said they were determined to fight the disease (vs. 68.0%); 61.7% of patients wanted to be kept informed of potential complications before they occurred (vs. 69.6%) and 81.2% wanted to be involved in therapeutic decisions (vs. 43.1%). Globally, patients had a more positive view of antifibrotic therapies than expected by pulmonologists: 41.5% evaluated their advantages superior to what they had expected (vs. 29.1% of patients according to pulmonologists) and 76.5% had a positive image of the benefits/disadvantages ratio (vs. 62.4%). Although pulmonologists had the impression that they were keeping their patients well-informed about exacerbations, hospital stays and the possible negative evolution of the disease despite antifibrotic therapies, 34.0%, 42.0% and 22.0% of patients respectively declared not being aware of these aspects. The feelings of patients suffering from IPF regarding their disease and treatment globally proved more positive compared with how pulmonologists perceived them. Taking into account the expectations and needs of patients may allow healthcare professionals to better address their needs and priorities.

Identifiants

pubmed: 33618076
pii: S2590-0412(20)30067-2
doi: 10.1016/j.resmer.2020.100811
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100811

Informations de copyright

Copyright © 2021 SPLF and Elsevier Masson SAS. All rights reserved.

Auteurs

V Cottin (V)

National reference coordinating center for rare lung diseases, pulmonology department, Louis-Pradel hospital, hospices civils de Lyon, UMR754, université de Lyon, université Claude-Bernard Lyon 1, INREA, member of OrphaLung, RespiFil, Radico-ILD, and ERN-LUNG, Lyon, France. Electronic address: vincent.cottin@chu-lyon.fr.

E Bergot (E)

Pulmonology department, University-affiliated hospital of Caen, Caen, France.

A Bourdin (A)

Pulmonology and addictology department, University-affiliated hospital of Montpellier, Montpellier, France.

H Nunes (H)

Pulmonology department, AP-HP, Avicenne University Hospital, Bobigny, France.

G Prévot (G)

Pulmonology department, Hospital of Toulouse, Toulouse, France.

B Wallaert (B)

Pulmonology and Allergy/immunology department, Regional University-affiliated hospital of Lille, Lille, France.

S Marchand-Adam (S)

Pulmonology department, Regional University-affiliated hospital of Tours, Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH